ReShape Lifesciences Inc. ( NASDAQ: RSLS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Michael Miller - Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

Novo and Lilly also market their GLP-1s for weight loss under, respectively, Wegovy (semaglutide) and Zepbound (tirzepatide). "In most countries, especially in low-income and middle-income countries, ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 ...

Eyeing Future Approaches to GLP-1s Commenting for TCTMD ... adding that “this is a conversation that doesn’t happen enough, ...

However, interest in GLP-1 drugs, particularly Ozempic, has also been fueled in part by social media discourse and ...

This is just a glimpse of the GLP-1 insights available to CivicScience clients. Want to see the full picture? Let’s talk.